Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Myasthenia gravis Exacerbation or Unmasking Associated With Telithromycin Treatment
Neurol 67:2256-2258, Perrot,S.,et al, 2006
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Primary CNS Lymphoma in Myasthenic on Long-term Azathioprine
J NeuroOncol 74:91-92, Finelli,P.F., 2005
Primary CNS Lymphoma Complicating Treatment of Myasthenia Gravis with Mycophenolate Mofetil
Neurol 65:639-641, Vernino,S.,et al, 2005
The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathol 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001
Association of Primary Central Nervous System Lymphoma with Long-Term Azathioprine Therapy for Myasthenia Gravis?
Ann Neurol 47: 682-683, Herrlinger,U.,et al, 2000
Iodinated Contrast Agents in Myasthenia Gravis
Neurol 37:1400-1402, Frank,J.H.,et al, 1987
The Pathophysiology of Penicillamine-Induced Myasthenia Gravis
Ann Neurol 20:740-744, Kuncl,R.W.,et al, 1986
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Severe Myotonic Crisis Resembling Malignant Hyperthermia
Neurol 104:e213497, Wadhwani,A.R.,et al, 2025
Postprocedural Brachial Neuritis:Clinical, Electrodiagnostic, and Neuroimaging Features
AJNR 46:1050-1055, Ambati,V.S.,et al, 2025
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Risk of First Ischaemic Stroke and Use of Antidopaminergic Antiemetics: Nationwide Case-Time-Control Study
BMJ 376:e061921, Benard-Laribiere, A.,et al, 2022
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Contrast-Induced Encephalopathy After Endovascular Thrombectomy for Acute Ischemic Stroke
Stroke 51:3756-3759, Chu, Y.I.,et al, 2020
Cerebrospinal Fluid Hypovolemia and Posterior Reversible Encephalopathy Syndrome
Front Neurol 11:591, Zheng,Y-y, et al, 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
A Misdiagnosis of Atypical Trigeminal Neuralgia
Neurol 93:124-131, Duvall, J.R. & Robertson, C.E., 2019
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Childhood Seizures After Phototherapy
Pediatrics 142:e20180648, Newman, T.B.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Management of Anticoagulants in Patients Undergoing Endoscopic Procedure
www.UptoDate.com, Dec, Kamath, P.S., 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Tranexamic Acid-Associated Seizures: Causes and Treatment
Ann Neurol 79:18-26, Lecker, I.,et al, 2016
Natalizumab-Related PML 2 Weeks after Negative Anti-JCV Antibody Assay
Neurol 86:484-486, Gagne, M.S.,et al, 2016
Metronidazole-Associated Encephalopathy
NEJM 374:1465, Baden, L.R., 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
NEJM 375:1131-1141,1185, Connolly, S.J.,et al, 2016
Clinical Relevance of Microbleeds in Acute Stroke Thrombolysis
Neurol 87:1534-1541, Charidimou, A.,et al, 2016
Stroke Risk and Mortality in Patients with Ventricular Assist Devices
Stroke 47:2702-2706,2677, Parikh, N.S.,et al, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Eur J Cancer 54:139-148, Michot, JM,.,et al, 2016
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Reversible Cerebral Vasoconstriction Syndromes
MedLink Aug, Singhai, A.B. & Levine, S.R., 2015
Growth Hormone Treatment for Childhood Short Stature and Risk of Stroke in Early Adulthood
Neurol 83:780-786, Poidvin, a.,et al, 2014